SAREPTA is resistant to the FDA on elements, the agency chooses the best drug regulator | Stat

Hello everyone, it’s Jason Mast, filling for Ed. Today, I am at the New York office in Pharmalittle, sipping a Bread’s Bakery coffee, which serves the best Babka in Manhattan. (The best babka in the country, for those who wonder, is that of my mother. She does not take orders, but if you are really, really nice to a certain statistical journalist …) Anyway, on the news….

Sarepta Therapeutics refused an American request for the Food and Drug Administration to stop the expeditions of Elevedys, its gene therapy for the muscular dystrophy of Duchenne, Stat Reports. The FDA published the request on Friday, after news appeared that a third patient, a 51 -year -old man, died after receiving genique therapy from Sarepta. The patient, who had a different shape of muscular dystrophy that the two boys who died previously, received a related but distinct treatment to elevations. It is not clear precisely what led the FDA to issue the request now – because the agency had already been aware of the death – or the way this dead end between the agency and the company will take place.

The FDA named George Tidmarsh as a new chief of the Center for Drug Evaluation and Research, Stat Notes. Tidmarsh, a long-standing doctor-scientific and executive of biotechnology, criticized the old high-level biological regulator Peter Marks and the agency’s approach in vaccination marketing. But as a former leader of the drug himself, he can be considered by industry as a more friendly choice than certain potential alternatives.